Mimedx (MDXG) Enterprise Value (2010 - 2026)
Mimedx recorded quarterly Enterprise Value of -$159.8 million in Q1 2026, up 3.82% quarter-over-quarter from -$166.1 million in Q4 2025, and down 50.12% year-over-year from -$320.3 million in Q1 2025.
Mimedx's Enterprise Value history runs 17 years deep, the most recent figure standing at -$159.8 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 50.12% year-over-year to -$159.8 million; the TTM figure through Mar 2026 stood at -$159.8 million (down 50.12% YoY), while the FY2025 annual figure was -$166.1 million, down 59.1% from the prior year.
- Enterprise Value came in at -$159.8 million for Q1 2026 at Mimedx, up from -$166.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$48.5 million in Q1 2024 to a low of -$166.1 million in Q4 2025.
- A 5-year average of -$94.0 million and a median of -$78.8 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value grew 24.27% in 2022 and plunged 119.5% in 2025, its largest moves.
- Mimedx's Enterprise Value stood at -$66.0 million in 2022, then decreased by 24.34% to -$82.0 million in 2023, then fell by 27.34% to -$104.4 million in 2024, then slumped by 59.1% to -$166.1 million in 2025, then climbed by 3.82% to -$159.8 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$159.8 million, -$166.1 million, and -$142.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | -159.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -159.77 Mn |
| Dec 31, 2025 | -166.12 Mn |
| Sep 30, 2025 | -142.08 Mn |
| Jun 30, 2025 | -118.87 Mn |
| Mar 31, 2025 | -106.43 Mn |
| Dec 31, 2024 | -104.42 Mn |
| Sep 30, 2024 | -88.80 Mn |
| Jun 30, 2024 | -69.04 Mn |
| Mar 31, 2024 | -48.49 Mn |
| Dec 31, 2023 | -82.00 Mn |
| Jun 30, 2023 | -68.65 Mn |
| Mar 31, 2023 | -61.22 Mn |
| Dec 31, 2022 | -65.95 Mn |
| Sep 30, 2022 | -73.22 Mn |
| Jun 30, 2022 | -72.50 Mn |
| Mar 31, 2022 | -75.68 Mn |
| Dec 31, 2021 | -87.08 Mn |
| Sep 30, 2021 | -90.61 Mn |
| Jun 30, 2021 | -85.01 Mn |
| Mar 31, 2021 | -84.75 Mn |
| Dec 31, 2020 | -95.81 Mn |
| Sep 30, 2020 | -109.60 Mn |
| Jun 30, 2020 | -48.20 Mn |
| Mar 31, 2020 | -53.50 Mn |
| Dec 31, 2019 | -69.07 Mn |
| Sep 30, 2019 | -94.12 Mn |
| Jun 30, 2019 | -96.90 Mn |
| Mar 31, 2019 | -28.38 Mn |
| Dec 31, 2018 | -45.12 Mn |
| Dec 31, 2017 | -27.48 Mn |
| Sep 30, 2017 | -36.52 Mn |
| Jun 30, 2017 | -47.53 Mn |
| Mar 31, 2017 | -30.92 Mn |
| Dec 31, 2016 | -30.32 Mn |
| Sep 30, 2016 | -18.34 Mn |
| Jun 30, 2016 | -23.80 Mn |
| Mar 31, 2016 | -17.62 Mn |
| Dec 31, 2015 | -29.30 Mn |
| Sep 30, 2015 | -47.57 Mn |
| Jun 30, 2015 | -45.85 Mn |
| Mar 31, 2015 | -44.70 Mn |
| Dec 31, 2014 | -52.33 Mn |
| Sep 30, 2014 | -47.25 Mn |
| Jun 30, 2014 | -39.25 Mn |
| Mar 31, 2014 | -43.02 Mn |
| Dec 31, 2013 | -44.08 Mn |
| Sep 30, 2013 | -6.06 Mn |
| Jun 30, 2013 | -4.19 Mn |
| Mar 31, 2013 | -5.73 Mn |
| Dec 31, 2012 | -6.75 Mn |
| Sep 30, 2012 | -7.62 Mn |
| Jun 30, 2012 | -2.65 Mn |
| Mar 31, 2012 | -3.02 Mn |
| Dec 31, 2011 | -4.11 Mn |
| Sep 30, 2011 | -637,192.00 |
| Jun 30, 2011 | -1.61 Mn |
| Mar 31, 2011 | -1.02 Mn |
| Dec 31, 2010 | -1.34 Mn |